Abstract
Iron deficiency anemia (IDA) is the most common type of anemia globally (IDA), the treatment being iron supplementation. However, in a few individuals, there is absent to suboptimal response to iron supplementation due to iron not being taken up by the body of the individual. This condition is known as iron-refractory IDA (IRIDA). Iron refractory iron deficiency anemia is a rare genetic condition that follows an autosomal recessive inheritance due to a defect in the TMPRSS6 gene encoding Matriptase-2. This protein is a transmembrane serine protease that plays an essential role in down-regulating hepcidin, the key regulator of iron homeostasis. Hallmarks of this disease are microcytic hypochromic anemia, low transferrin saturation, and normal/high serum hepcidin values. The anemia appears in the post-natal period, although in some cases it is only diagnosed in adulthood. The disease is refractory to oral iron treatment but shows a slow response to intravenous iron injections and partial correction of the anemia. This condition is likely being missed or under-diagnosed in our iron deficient endemic setting due to a lack of general awareness amongst physicians in establishing the diagnosis or due to the lack of availability of proper genetic testing.
Topics

No keywords indexed for this article. Browse by subject →

References
40
[1]
Camaschella C, Iron deficiency anemia.N Engl J Med 2015;372(19):1832-43 10.1056/nejmra1401038
[2]
Kapil U, Bhadoria A, National Iron-plus Initiative guidelines for control of iron deficiency anaemia in India.Natl Med J India 2013;27:27-9
[3]
Darshan D, Anderson GJ, Interacting signals in the control of hepcidin expression.Biometals 2009;22(1):77-87 10.1007/s10534-008-9187-y
[4]
Bhatia P, Jain R, Singh A, A structured approach to iron refractory iron deficiency anemia (IRIDA) diagnosis (SAID): The more is “SAID” about iron, the less it is.Pediatr Hematol Oncol J 2017;2:48-53 10.1016/j.phoj.2017.08.003
[5]
Finberg KE, Iron-refractory iron deficiency anemia.Semin Hematol 2009;46(4):378-86 10.1053/j.seminhematol.2009.06.006
[6]
Fernandez S, IRIDA syndrome. Orphanet..
[7]
Hershko C, Camaschella C, How I treat unexplained refractory iron deficiency anemia.Blood 2014;123(3):326-33 10.1182/blood-2013-10-512624
[8]
Buchanan GR, Sheehan RG, Malabsorption and defective utilization of iron in three siblings.J Pediatr 1981;98:723-8 10.1016/s0022-3476(81)80831-1
[9]
Brown AC, Lutton JD, Pearson HA, Nelson JC, Levere RD, Abraham NG, Heme metabolism and in vitro erythropoiesis in anemia associated with hypochromic microcytosis.Am J Hematol 1988;27(1):1-6 10.1002/ajh.2830270102
[10]
Hartman KR, Barker JA, Microcytic anemia with iron malabsorption: an inherited disorder of iron metabolism.Am J Hematol 1996;51(4):269-75 10.1002/(sici)1096-8652(199604)51:4<269::aid-ajh4>3.0.co;2-u
[11]
Pearson HA, Lukens JN, Ferrokinetics in the syndrome of familial hypoferremic microcytic anemia with iron malabsorption.J Pediatr Hematol Oncol 1999;21(5):412-7 10.1097/00043426-199909000-00014
[12]
Finberg K, Heeney M, Campagna D, Aydinok Y, Pearson H, Hartman K, Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA).Nat Genet 2008;40(5):569-71 10.1038/ng.130
[13]
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization

Elizabeta Nemeth, Marie S. Tuttle, Julie Powelson et al.

Science 10.1126/science.1104742
[14]
Darshan D, Anderson GJ, Interacting signals in the control of hepcidin expression.Biometals 2009;22(1):77-87 10.1007/s10534-008-9187-y
[15]
Iorember F, Aviles D, Anemia in nephrotic syndrome: approach to evaluation and treatment.Pediatr Nephrol 2017;32:1323-30 10.1007/s00467-016-3555-6
[16]
Kodama K, Noguchi A, Adachi H, Hebiguchi M, Yano M, Takahashi T, Novel mutation in the TMPRSS6 gene with iron-refractory iron deficiency anemia.Pediatr Int 2014;56:41-4 10.1111/ped.12395
[17]
[18]
Ramsay AJ, Reid JC, Velasco G, Quigley JP, Hooper JD, The type II transmembrane serine protease matriptase-2--identification, structural features, enzymology, expression pattern and potential roles.Front Biosci 2008;13:569-79 10.2741/2702
[19]
Wang CY, Meynard D, Lin HY, The role of TMPRSS6/matriptase-2 in iron regulation and anemia.Front Pharmacol 2014;5:114 10.3389/fphar.2014.00114
[20]
Shokrgozar N, Golafshan HA, Molecular perspective of iron uptake, related diseases, and treatments.Blood Res 2019;54(1):10-6 10.5045/br.2019.54.1.10
[21]
Falco LD, Sanchez M, Silvestri L, Kannengiesser C, Muckenthaler MU, Iolascon A, Iron refractory iron deficiency anemia.Haematologica 2013;98(6):845-53 10.3324/haematol.2012.075515
[22]
Ramsay AJ, Hooper JD, Folgueras AR, Velasco G, López-Otín C, Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis.Haematologica 2009;94(6):840-9 10.3324/haematol.2008.001867
[23]
Du X, She E, Gelbart T, Truksa J, Lee P, Xia Y, The serine protease TMPRSS6 is required to sense iron deficiency.Science 2008;320(5879):1088-92 10.1126/science.1157121
[24]
Meynard D, Babitt JL, Lin HY, The liver: conductor of systemic iron balance.Blood 2014;123(2):168-76 10.1182/blood-2013-06-427757
[25]
Kautz L, Meynard D, Monnier A, Darnaud V, Bouvet R, Wang RH, Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver.Blood 2008;112(4):1503-9 10.1182/blood-2008-03-143354
[26]
Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Lack of the bone morphogenetic protein BMP6 induces massive iron overload.Nat Genet 2009;41(4):478-81 10.1038/ng.320
[27]
Silvestri L, Pagani A, Nai A, Domenico ID, Kaplan J, Camaschella C, The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin.Cell Metab 2008;8(6):502-11 10.1016/j.cmet.2008.09.012
[28]
Truksa J, Gelbart T, Peng H, Beutler E, Beutler B, Lee P, Suppression of the hepcidin-encoding gene Hamp permits iron overload in mice lacking both hemojuvelin and matriptase-2/ TMPRSS6.Br J Haematol 2009;147(4):571-81 10.1111/j.1365-2141.2009.07873.x
[29]
Finberg KE, Whittlesey RL, Fleming MD, Andrews NC, Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis.Blood 2010;115(18):3817-26 10.1182/blood-2009-05-224808
[30]
Lenoir A, Deschemin JC, Kautz L, Ramsay AJ, Roth MP, Lopez-Otin C, Iron-deficiency anemia from matriptase2 inactivation is dependent on the presence of functional Bmp6.Blood 2011;117(2):647-50 10.1182/blood-2010-07-295147
[31]
Bhatia P, Singh A, Hegde A, Jain R, Bansal D, Systematic evaluation of paediatric cohort with iron refractory iron deficiency anaemia (IRIDA) phenotype reveals multiple TMPRSS6 gene variations.Br J Haematol 2017;177(2):311-8 10.1111/bjh.14554
[32]
Athiyarath R, Shaktivel K, Abraham V, Singh D, Bondu JD, Chapla A, Association of genetic variants with response to iron supplements in pregnancy.Genes Nutr 2015;10(5):25 10.1007/s12263-015-0474-2
[33]
Sharma P, Bhatia P, Singh M, Jamwal M, Pallavelangini S, Das R, Comprehensive Genomic Analysis Identifies a Diverse Landscape of Sideroblastic and Nonsideroblastic Iron-Related Anemias with Novel and Pathogenic Variants in an Iron-Deficient Endemic Setting.J Mol Diagn 2024;26(5):430-44 10.1016/j.jmoldx.2024.01.011
[34]
Donker AE, Raymakers RAP, Vlasveld LT, Barneveld TV, Terink R, N Dors, Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis.Blood 2014;123(25):3873-86 10.1182/blood-2014-01-548776
[35]
Beutler E, Geet CV, Loo DMWMt, Gelbart T, Crain K, Truksa J, Polymorphisms and mutations of human TMPRSS6 in iron deficiency anemia.Blood Cells Mol Dis 2010;44(1):16-21 10.1016/j.bcmd.2009.09.001
[36]
Guillem F, Kannengiesser C, Oudin C, Lenoir A, Matak P, Donadieu J, Inactive matriptase-2 mutants found in IRIDA patients still repress hepcidin in a transfection assay despite having lost their serine protease activity.Hum Mutat 2012;33(9):1388-96 10.1002/humu.22116
[37]
Khuong-Quang D, Schwartzentruber J, Westerman M, Lepage P, Finberg KE, Iron Refractory Iron Deficiency Anemia: Presentation With Hyperferritinemia and Response to Oral Iron Therapy.Pediatrics 2013;131(2):620-5 10.1542/peds.2012-1303
[38]
Cau M, Galanello R, Giagu N, Melis MA, Responsiveness to oral iron and ascorbic acid in a patient with IRIDA.Blood Cells Mol Dis 2012;48(2):121-3 10.1016/j.bcmd.2011.11.007
[39]
Melis MA, Cau M, Congiu R, Sole G, Barella S, Cao A, A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron.Haematologica 2008;93(10):1473-9 10.3324/haematol.13342
[40]
Ramsay AJ, Quesada V, Sanchez M, Garabaya C, Sarda MP, Baiget M, Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms.Hum Mol Genet 2009;18(19):3673-83 10.1093/hmg/ddp315
Metrics
0
Citations
40
References
Details
Published
Jul 15, 2024
Vol/Issue
11(2)
Pages
108-118
License
View
Cite This Article
Preeti Tripathi, Rama Hariharan, Umesh Kapoor (2024). IRIDA- An Indian perspective. Indian Journal of Pathology and Oncology, 11(2), 108-118. https://doi.org/10.18231/j.ijpo.2024.026